gilead sciences news - Search News

Gilead, leo pharma

Gilead Continues Diversification Drive With Potential $1.7B Inflammation Pact With LEO

Gilead’s potential investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 and IL-13 signaling, which in turn are known inflammatory targets.

FierceBiotech · 1d

Gilead roars into JPM25, inking $1.7B inflammation deal with Leo Pharma

Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more deeply than before, into inflammation, penning a major $1.7 billion deal wit | Gilead continues its divergence out of its original infectious disease beginnings and into cancer and now,

Reuters · 1d

Gilead, LEO Pharma partner to develop programs for inflammatory diseases

Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat patients with inflammatory diseases.

PharmaTimes · 4h

Gilead and LEO Pharma partner to develop oral STAT6 program

Gilead Sciences and LEO Pharma have announced a strategic partnership to advance LEO Pharma’s oral STAT6 program. This collaboration aims to develop treatments for patients suffering from inflammatory diseases such as atopic dermatitis, asthma, and COPD.

Business Wire · 1d

Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases

Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and commercialization of LEO

Business Insider · 1d

Gilead, LEO Pharma Enter Strategic Partnership To Accelerate Development Of Oral STAT6 Program

Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule

Bloomberg L.P. · 1d

Gilead, Leo Pharma Form Pact Focused on Inflammatory Diseases

Gilead Sciences and LEO Pharma said they formed a strategic partnership to focus on the potential treatment of patients with inflammatory diseases.

bovnews55m

Gilead Sciences Inc (GILD) Reported a 37.45% Operating Margin Last Year—What’s the Real Story?

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $89.88 which represents a slight increase of $0.74 or 0.83% from the prior close of $89.14. The stock opened at $90.19 and ...

1don MSN

Gilead in pact for anti-inflammatory drugs in a deal worth up to $1.7B

Gilead Sciences (GILD) partners with LEO Pharma in a $1.7B agreement to develop anti-inflammatory drugs. Read more here.

FierceBiotech5d

Galapagos splits in 2, laying off 40% of staff, shrinking pipeline and ending Gilead partnership

After the separation, Gilead will hold around 25% of the outstanding shares in both Galapagos and the spin-off company. While ...

Gilead Sciences (NASDAQ:GILD) Upgraded at Morgan Stanley

Morgan Stanley upgraded shares of Gilead Sciences (NASDAQ:GILD – Free Report) from an equal weight rating to an overweight rating in a research note published on Friday, MarketBeat.com reports. Morgan ...